Back to top
more

Galmed Pharmaceuticals (GLMD)

(Real Time Quote from BATS)

$0.38 USD

0.38
9,071

0.00 (0.34%)

Updated Apr 19, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada

by Zacks Equity Research

Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.

Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals

by Zacks Equity Research

Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.

Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J

by Zacks Equity Research

Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.

CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

by Zacks Equity Research

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down

by Zacks Equity Research

Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

by Zacks Equity Research

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.

Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

by Zacks Equity Research

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat

by Zacks Equity Research

Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.

Intercept (ICPT) Posts New Positive Results on NASH Drug

by Zacks Equity Research

Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.

Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.

Intercept Slumps as the FDA Issues CRL to NASH Candidate

by Zacks Equity Research

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

How Galmed (GLMD) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher

by Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Top Ranked Momentum Stocks to Buy for December 4th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 4th

Ekta Bagri headshot

NASH Scorecard Year to Date: The Winners and the Losers

by Ekta Bagri

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018

by Zacks Equity Research

Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.

Novan Announces Top-Line Data From Mid-Stage Molluscum Study

by Zacks Equity Research

Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.

Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher

by Zacks Equity Research

Galmed Pharmaceuticals (GLMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Galmed Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 64.29% and 400.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?